JP2014501929A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501929A5 JP2014501929A5 JP2013547903A JP2013547903A JP2014501929A5 JP 2014501929 A5 JP2014501929 A5 JP 2014501929A5 JP 2013547903 A JP2013547903 A JP 2013547903A JP 2013547903 A JP2013547903 A JP 2013547903A JP 2014501929 A5 JP2014501929 A5 JP 2014501929A5
- Authority
- JP
- Japan
- Prior art keywords
- sample
- bladder cancer
- subject
- cell
- specific binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010005003 Bladder cancer Diseases 0.000 claims 11
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 11
- 201000005112 urinary bladder cancer Diseases 0.000 claims 11
- 230000009870 specific binding Effects 0.000 claims 9
- 230000027455 binding Effects 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 238000005259 measurement Methods 0.000 claims 4
- 210000001124 body fluid Anatomy 0.000 claims 3
- 239000010839 body fluid Substances 0.000 claims 3
- 238000012423 maintenance Methods 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1100223.5A GB201100223D0 (en) | 2011-01-07 | 2011-01-07 | Diagnostic method |
| GB1100223.5 | 2011-01-07 | ||
| PCT/GB2012/000008 WO2012093251A1 (en) | 2011-01-07 | 2012-01-06 | Diagnostic method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014501929A JP2014501929A (ja) | 2014-01-23 |
| JP2014501929A5 true JP2014501929A5 (enExample) | 2015-11-12 |
Family
ID=43663908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013547903A Pending JP2014501929A (ja) | 2011-01-07 | 2012-01-06 | 診断方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10107814B2 (enExample) |
| EP (2) | EP3214445B1 (enExample) |
| JP (1) | JP2014501929A (enExample) |
| AU (1) | AU2012204796A1 (enExample) |
| CA (1) | CA2823460A1 (enExample) |
| GB (1) | GB201100223D0 (enExample) |
| IL (1) | IL227295A0 (enExample) |
| WO (1) | WO2012093251A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11054426B2 (en) * | 2011-01-07 | 2021-07-06 | Cytosystems Ltd | Diagnostic method |
| US11519916B2 (en) | 2015-06-08 | 2022-12-06 | Arquer Diagnostics Limited | Methods for analysing a urine sample |
| ES2911415T3 (es) | 2015-06-08 | 2022-05-19 | Arquer Diagnostics Ltd | Métodos y kits |
| GB201511196D0 (en) | 2015-06-25 | 2015-08-12 | Cytosystems Ltd | Monoclonal antibodies |
| WO2021242637A1 (en) * | 2020-05-28 | 2021-12-02 | Cytobay Inc. | Cytopathological staining |
| EP4217746A1 (en) * | 2020-09-24 | 2023-08-02 | Cytosystems Limited | Diagnosis of cancer by imaging flow cytometry |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303323B1 (en) * | 1997-10-21 | 2001-10-16 | Cancer Research Campaign Technology Limited | Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies |
| EP1888238B1 (en) * | 2005-04-21 | 2014-08-13 | California Institute of Technology | Parylene membrane filters |
-
2011
- 2011-01-07 GB GBGB1100223.5A patent/GB201100223D0/en not_active Ceased
-
2012
- 2012-01-06 EP EP16205472.0A patent/EP3214445B1/en not_active Not-in-force
- 2012-01-06 EP EP12701160.9A patent/EP2661628B1/en not_active Not-in-force
- 2012-01-06 JP JP2013547903A patent/JP2014501929A/ja active Pending
- 2012-01-06 AU AU2012204796A patent/AU2012204796A1/en not_active Abandoned
- 2012-01-06 WO PCT/GB2012/000008 patent/WO2012093251A1/en not_active Ceased
- 2012-01-06 CA CA2823460A patent/CA2823460A1/en not_active Abandoned
- 2012-01-06 US US13/512,585 patent/US10107814B2/en active Active
-
2013
- 2013-07-02 IL IL227295A patent/IL227295A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014501929A5 (enExample) | ||
| JP2014144959A5 (enExample) | ||
| MX2014003295A (es) | Metodos para vigilar la capacidad de respuesta a la terapia anti-smad7. | |
| NZ700695A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| MX2020004617A (es) | Prediccion de riesgo de evento cardiovascular y usos del mismo. | |
| IN2014CN01787A (enExample) | ||
| WO2014186761A3 (en) | Methods for determining responsiveness to an anti-cd47 agent | |
| WO2012075506A3 (en) | Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses | |
| GB201209668D0 (en) | Methods of monitoring conditions by sequence analysis | |
| PH12014501138A1 (en) | Il-1 binding proteins | |
| NZ593514A (en) | p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer | |
| JP2010207229A5 (enExample) | ||
| NZ605698A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| EP2757365A3 (en) | Capacitance detection in electrochemical assay with improved response | |
| HK1259001A1 (zh) | 癌症的预後和诊断方法 | |
| EP2619587A4 (en) | BIOMARKER FOR PREDICTING THE REPRODUCTION OF A COLORECTAL CARCINOMA | |
| WO2011104517A3 (en) | Capacitance detection in electrochemical assay | |
| WO2014162008A3 (en) | Biomarker signatures for predicting drug response in hodkin's lymphoma | |
| GB201014837D0 (en) | Biomarker signatures and uses thereof | |
| MX2015001961A (es) | Metodos y sistemas para ensayos. | |
| JP2015520378A5 (enExample) | ||
| HK1215875A1 (zh) | 用於监视放射治疗癌症反应的方法和试剂盒 | |
| WO2013167727A3 (en) | Method for determining arthritis relapse risk | |
| GB201201593D0 (en) | Evaluating and optimizing a trajectory function | |
| WO2011122634A8 (ja) | 肺腺がんの予後予測方法、肺腺がんの検出キット、および、肺腺がんを治療するための医薬組成物 |